Cutler Group LP Altimmune, Inc. Call Options Transaction History

Cutler Group LP

15 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 Apr 19, 2024	SELL	$8.22 - $13.81 $34,524 - $58,002	-4,200 Reduced 66.67%	2,100 $6,000
Q4 2023 Jan 18, 2024	BUY	$2.14 - $11.62 $6,420 - $34,860	3,000 Added 90.91%	6,300 $12,000
Q3 2023 Nov 07, 2023	BUY	$2.4 - $3.45 $480 - $690	200 Added 6.45%	3,300 $0
Q2 2023 Jul 18, 2023	SELL	$3.45 - $5.97 $77,625 - $134,325	-22,500 Reduced 87.89%	3,100 $0
Q1 2023 May 01, 2023	SELL	$4.19 - $16.83 $7,542 - $30,293	-1,800 Reduced 6.57%	25,600 $2,000
Q4 2022 Feb 07, 2023	BUY	$8.74 - $16.45 $143,336 - $269,780	16,400 Added 149.09%	27,400 $117,000
Q3 2022 Oct 25, 2022	BUY	$10.67 - $22.41 $117,370 - $246,510	11,000 New	11,000 $36,000
Q1 2022 Apr 14, 2022	SELL	$5.9 - $9.45 $15,340 - $24,569	-2,600 Closed	0 $0
Q4 2021 Jan 18, 2022	SELL	$8.69 - $12.48 $344,124 - $494,208	-39,600 Reduced 93.84%	2,600 $0
Q3 2021 Oct 26, 2021	BUY	$8.43 - $16.81 $324,555 - $647,185	38,500 Added 1040.54%	42,200 $9,000
Q2 2021 Jul 19, 2021	BUY	$9.85 - $16.46 $11,820 - $19,752	1,200 Added 48.0%	3,700 $1,000
Q4 2020 Jan 21, 2021	BUY	$7.84 - $14.22 $10,192 - $18,486	1,300 Added 108.33%	2,500 $6,000
Q3 2020 Oct 27, 2020	SELL	$9.93 - $33.26 $176,754 - $592,028	-17,800 Reduced 93.68%	1,200 $1,000
Q2 2020 Jul 22, 2020	BUY	$2.9 - $10.71 $54,810 - $202,419	18,900 Added 18900.0%	19,000 $63,000
Q1 2020 May 07, 2020	BUY	$1.69 - $3.8 $169 - $380	100 New	100 $0

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $370M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.